Schizophrenia Clinical Trial
Official title:
Adapted Cognitive/Affective Remediation for Cannabis Misuse in Schizophrenia
This study will integrate and adapt a cognitive remediation (Cognitive Enhancement Therapy [CET]) and an affect regulation (Personal Therapy [PT]) intervention for 50 individuals with schizophrenia that misuse cannabis. Participants will be randomized to CET/PT plus treatment as usual (TAU) or TAU alone and treated for 18 months.
Schizophrenia is a severe and chronic mental illness that places significant burden on the
individuals who suffer from it, their families, and society. One of the most vexing problems
in the treatment of schizophrenia is the high rate of substance use comorbidity. The majority
of schizophrenia patients experience substantial cognitive and affective impairments.
Consistent deficits have been observed in the broad domains of neurocognition(e.g.,
attention, memory, and problem-solving), social cognition (e.g., perspective-taking,
foresight, social cue recognition), and affect regulation, which are major contributors to
functional impairment in the disorder. These cognitive and affective deficits may be
exacerbated among schizophrenia patients that misuse substances and because these deficits
are untreated by current pharmacotherapeutic strategies many turn to cannabis and other drugs
to cope.
Cognitive Enhancement Therapy (CET) is a treatment that has proved effective in improving
cognition in individuals with schizophrenia. Personal Therapy (PT) is a treatment designed to
help individuals with the affective deficits that may lead to substance misuse for
individuals with schizophrenia. This study will adapt and integrate CET and PT to test
whether this intervention is better or more effective for treating substance misusing
schizophrenia patients than the usual treatment received (Treatment as Usual or TAU).
Participation in this study will last 18 months. Eligible participants will be randomly
assigned to receive either CET/PT or TAU. Participants that receive the CET/PT condition must
be able to attend weekly treatment sessions in Pittsburgh, PA. All participants will complete
cognitive, functional, and affective outcome measures at the beginning of the study,
6-months, 12-months, and at 18-months regardless of treatment assignment. Results from all
outcome measures will be used to estimate the effectiveness of CET/PT for individuals that
have schizophrenia and misuse substances.
;
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Recruiting |
NCT05039489 -
A Study on the Brain Mechanism of cTBS in Improving Medication-resistant Auditory Hallucinations in Schizophrenia
|
N/A | |
| Completed |
NCT05321602 -
Study to Evaluate the PK Profiles of LY03010 in Patients With Schizophrenia or Schizoaffective Disorder
|
Phase 1 | |
| Completed |
NCT05111548 -
Brain Stimulation and Cognitive Training - Efficacy
|
N/A | |
| Completed |
NCT04503954 -
Efficacy of Chronic Disease Self-management Program in People With Schizophrenia
|
N/A | |
| Completed |
NCT02831231 -
Pilot Study Comparing Effects of Xanomeline Alone to Xanomeline Plus Trospium
|
Phase 1 | |
| Completed |
NCT05517460 -
The Efficacy of Auricular Acupressure on Improving Constipation Among Residents in Community Rehabilitation Center
|
N/A | |
| Completed |
NCT03652974 -
Disturbance of Plasma Cytokine Parameters in Clozapine-Resistant Treatment-Refractory Schizophrenia (CTRS) and Their Association With Combination Therapy
|
Phase 4 | |
| Recruiting |
NCT04012684 -
rTMS on Mismatch Negativity of Schizophrenia
|
N/A | |
| Recruiting |
NCT04481217 -
Cognitive Factors Mediating the Relationship Between Childhood Trauma and Auditory Hallucinations in Schizophrenia
|
N/A | |
| Completed |
NCT00212784 -
Efficacy and Safety of Asenapine Using an Active Control in Subjects With Schizophrenia or Schizoaffective Disorder (25517)(P05935)
|
Phase 3 | |
| Completed |
NCT04092686 -
A Clinical Trial That Will Study the Efficacy and Safety of an Investigational Drug in Acutely Psychotic People With Schizophrenia
|
Phase 3 | |
| Completed |
NCT01914393 -
Pediatric Open-Label Extension Study
|
Phase 3 | |
| Recruiting |
NCT03790345 -
Vitamin B6 and B12 in the Treatment of Movement Disorders Induced by Antipsychotics
|
Phase 2/Phase 3 | |
| Recruiting |
NCT05956327 -
Insight Into Hippocampal Neuroplasticity in Schizophrenia by Investigating Molecular Pathways During Physical Training
|
N/A | |
| Terminated |
NCT03261817 -
A Controlled Study With Remote Web-based Adapted Physical Activity (e-APA) in Psychotic Disorders
|
N/A | |
| Terminated |
NCT03209778 -
Involuntary Memories Investigation in Schizophrenia
|
N/A | |
| Completed |
NCT02905604 -
Magnetic Stimulation of the Brain in Schizophrenia or Depression
|
N/A | |
| Recruiting |
NCT05542212 -
Intra-cortical Inhibition and Cognitive Deficits in Schizophrenia
|
N/A | |
| Completed |
NCT04411979 -
Effects of 12 Weeks Walking on Cognitive Function in Schizophrenia
|
N/A | |
| Terminated |
NCT03220438 -
TMS Enhancement of Visual Plasticity in Schizophrenia
|
N/A |